Showing results (61-70 of 443) with videos related to

Sort By:
Pageof 45
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 31, 2011
Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantationRon Ram, Barry Storer, Marco Mielcarek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2004
Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigensScott S Tykodi, Edus H Warren, John A Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2025
Sirolimus and Cyclosporine With Post-Transplant Cyclophosphamide or Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Hematopoietic Cell TransplantationMasumi Ueda Oshima, Phuong T Vo, Michael Boeckh, et al.
British Journal of Haematology|May 29, 2010
Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomasAndrei R Shustov, Theodore A Gooley, Brenda M Sandmaier, et al.
Experimental Hematology|October 11, 2003
Relapse or progression after hematopoietic cell transplantation using nonmyeloablative conditioning: effect of interventions on outcomeWolfgang A Bethge, Barry E Storer, Michael B Maris, et al.
British Journal of Haematology|July 22, 2015
Pre-transplant comorbidity burden and post-transplant chronic graft-versus-host diseaseJennifer E Vaughn, Ted Gooley, Richard T Maziarz, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 26, 2013
Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell doseMerav Bar, Brenda M Sandmaier, Yoshihiro Inamoto, et al.
Pageof 45